Regulation of PTEN Activity in Cancer Cells
癌细胞中 PTEN 活性的调节
基本信息
- 批准号:6916266
- 负责人:
- 金额:$ 30.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-01 至 2007-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Regulation of PTEN activity and translocation in normal and cancer cells. PTEN (phosphatase and tensin homolog deleted on chromosome ten) is a recently identified tumor suppressor, which is deleted/mutated in human tumors including glioblastomas, carcinomas of the prostate, uterus, bladder and breast and malignant melanomas. PTEN dephosphorylates the 3-position of phosphatidylinositol (Pdtlns)-3-phosphates, thus, preventing activation of Akt by Ptdlns-3-kinase. PTEN also dephosphorylates focal adhesion kinase (p125FAK) and Shc, a SH2-phosphotyrosine-binding adapter protein that links tyrosine kinases to Ras signaling and the MAP kinase pathway. PTEN contains a C2 lipid binding domain at its C-terminal end, which is responsible for its' binding to phosphatidylcholine at the inner leaflet of the plasma membrane in a Ca2+-independent manner. It has been suggested that this domain may influence the activity of the protein, but no clear-cut role for the C2 domain of PTEN has been proposed.We have recently found that a small redox protein, thioredoxin, binds directly to the C2 domain of PTEN and thereby is able to negatively regulate the lipid activity of PTEN. Thioredoxin binds to the Cys212 of PTEN forming a stable complex, which can be regulated in a redox dependent manner. Moreover, the addition of selenium to cells, which is know to increase thioredoxin reductase activity, is able to restore PTEN activity.Hence, the hypotheses upon which our studies are based are that 1) PTEN activity is allosterically regulated by a small redox protein and indirectly by selenium and that 2) PTEN activity can be regulated indirectly by its C2 domain. The objectives of our proposed studies are directed towards a better understanding of the role of the C2 domain in the translocation of PTEN and in the regulation of the activity of PTEN via its interaction with other proteins.
描述(由申请人提供):正常细胞和癌细胞中PTEN活性和易位的调节。PTEN(10号染色体上缺失的磷酸酶和紧张素同源物)是最近发现的一种肿瘤抑制因子,在人类肿瘤中缺失/突变,包括胶质母细胞瘤、前列腺癌、子宫癌、膀胱癌、乳腺癌和恶性黑色素瘤。PTEN使磷脂酰肌醇(Pdtlns)-3-磷酸的3位去磷酸化,从而阻止pttlns -3-激酶活化Akt。PTEN还能使局灶黏附激酶(p125FAK)和Shc去磷酸化,Shc是一种将酪氨酸激酶与Ras信号和MAP激酶途径连接起来的sh2 -磷酸酪氨酸结合适配器蛋白。PTEN在其c端含有一个C2脂质结合域,负责以Ca2+不依赖的方式与质膜内小叶的磷脂酰胆碱结合。有人认为该结构域可能影响蛋白的活性,但PTEN的C2结构域没有明确的作用。我们最近发现一个小的氧化还原蛋白,硫氧还蛋白,直接结合到PTEN的C2结构域,从而能够负向调节PTEN的脂质活性。硫氧还蛋白与PTEN的Cys212结合形成稳定的复合物,可以通过氧化还原依赖的方式进行调节。此外,在细胞中添加硒,已知可以增加硫氧还蛋白还原酶的活性,能够恢复PTEN的活性。因此,我们的研究基于以下假设:1)PTEN活性受一个小氧化还原蛋白的变构调节,并间接受硒的调节;2)PTEN活性可由其C2结构域间接调节。我们提出的研究目标是为了更好地理解C2结构域在PTEN易位中的作用,以及通过与其他蛋白质的相互作用来调节PTEN的活性。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells.
亚硒酸钠在DU-145前列腺癌细胞中增加了肿瘤抑制蛋白PTEN的活性。
- DOI:10.1080/01635580802521338
- 发表时间:2009
- 期刊:
- 影响因子:0
- 作者:Berggren M;Sittadjody S;Song Z;Samira JL;Burd R;Meuillet EJ
- 通讯作者:Meuillet EJ
Regulation of the activity of the tumor suppressor PTEN by thioredoxin in Drosophila melanogaster.
- DOI:10.1016/j.yexcr.2007.01.004
- 发表时间:2007-04
- 期刊:
- 影响因子:3.7
- 作者:Zuohe Song;N. Saghafi;V. Gokhale;Marc C. Brabant;E. Meuillet
- 通讯作者:Zuohe Song;N. Saghafi;V. Gokhale;Marc C. Brabant;E. Meuillet
Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine.
- DOI:10.1021/ja807601b
- 发表时间:2009-12-23
- 期刊:
- 影响因子:15
- 作者:Block KM;Wang H;Szabó LZ;Polaske NW;Henchey LK;Dubey R;Kushal S;László CF;Makhoul J;Song Z;Meuillet EJ;Olenyuk BZ
- 通讯作者:Olenyuk BZ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Emmanuelle Joelle Meuillet其他文献
Emmanuelle Joelle Meuillet的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Emmanuelle Joelle Meuillet', 18)}}的其他基金
Selectivity and Efficacy of CD90-targeted Phase Shift Microbubbles for HIFU-mediated Non-Thermal Ablation of Brain Tumors.
CD90 靶向相移微泡对 HIFU 介导的脑肿瘤非热消融的选择性和功效。
- 批准号:
10547718 - 财政年份:2022
- 资助金额:
$ 30.2万 - 项目类别:
Ultrasound-mediated thrombolysis for MVO and PAO treatment.
用于 MVO 和 PAO 治疗的超声介导溶栓。
- 批准号:
10447822 - 财政年份:2021
- 资助金额:
$ 30.2万 - 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
- 批准号:
8260374 - 财政年份:2010
- 资助金额:
$ 30.2万 - 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
- 批准号:
8658015 - 财政年份:2010
- 资助金额:
$ 30.2万 - 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
- 批准号:
8088072 - 财政年份:2010
- 资助金额:
$ 30.2万 - 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
- 批准号:
7985087 - 财政年份:2010
- 资助金额:
$ 30.2万 - 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
- 批准号:
8447552 - 财政年份:2010
- 资助金额:
$ 30.2万 - 项目类别:
Novel AKT PH domain inhibitors to prevent skin cancer
新型 AKT PH 域抑制剂可预防皮肤癌
- 批准号:
7788398 - 财政年份:2009
- 资助金额:
$ 30.2万 - 项目类别:
Novel AKT PH domain inhibitors to prevent skin cancer
新型 AKT PH 域抑制剂可预防皮肤癌
- 批准号:
7937893 - 财政年份:2009
- 资助金额:
$ 30.2万 - 项目类别:
相似海外基金
ROLE OF CELL ADHESION IN BIOLOGICAL SIGNAL TRANSDUCTION
细胞粘附在生物信号转导中的作用
- 批准号:
6238317 - 财政年份:1997
- 资助金额:
$ 30.2万 - 项目类别:
ROLE OF CELL ADHESION IN BIOLOGICAL SIGNAL TRANSDUCTION
细胞粘附在生物信号转导中的作用
- 批准号:
5210031 - 财政年份:
- 资助金额:
$ 30.2万 - 项目类别: